The synthetic form of exendin-4, known as exenatide , became the first GLP-1 receptor agonist licensed for clinical use in the EU in 2006
General weight-based guidelines for 5 amino 1mq injection dosage suggest: Under 150 lbs: 50-75mg daily 150-200 lbs: 75mg daily (standard protocol) Over 200 lbs: 75-100mg daily Individuals with obesity: May require up to 100mg daily under medical supervision These guidelines serve as starting points, with final dosing determined by individual response, tolerance, and metabolic goals
Media description (scene 2): The number on the scale climbs to 280
(Wilding JPH et al., NEJM 2021) The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg in adults with existing cardiovascular disease and overweight or obesity but without diabetes (Lincoff AM et al., NEJM 2023)
JavaScript is Disabled in your browser